BR112013003899A2 - domínio variável único da imunoglobina anti-albumina sérica (sa), ligando multiespecífico, proteína de fusão, composição, ácido nucleico, vetor, célula hospedeira isolada, e, método de tratar ou previnir uma doença ou distúrbio em um paciente - Google Patents
domínio variável único da imunoglobina anti-albumina sérica (sa), ligando multiespecífico, proteína de fusão, composição, ácido nucleico, vetor, célula hospedeira isolada, e, método de tratar ou previnir uma doença ou distúrbio em um pacienteInfo
- Publication number
- BR112013003899A2 BR112013003899A2 BR112013003899A BR112013003899A BR112013003899A2 BR 112013003899 A2 BR112013003899 A2 BR 112013003899A2 BR 112013003899 A BR112013003899 A BR 112013003899A BR 112013003899 A BR112013003899 A BR 112013003899A BR 112013003899 A2 BR112013003899 A2 BR 112013003899A2
- Authority
- BR
- Brazil
- Prior art keywords
- disorder
- vector
- disease
- patient
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Endocrinology (AREA)
Abstract
domínio variável único da imunoglobina anti-albumina sérica (sa), ligando multiespecífico, proteína de fusão, composição, ácido nucleico, vetor, célula hospedeira isolada, e, método de tratar ou previnir uma doença ou distúrbio em um paciente. a invenção diz respeito a variantes melhoradas do domínio variável único da imunoglobulina anti-albumina sérica dom7h-14-10, assim como ligandos e conjugados medicamentosos que compreendem tais variantes, composições, ácidos nucleicos, vetores e hospedeiros.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37532810P | 2010-08-20 | 2010-08-20 | |
PCT/EP2011/064000 WO2012022703A2 (en) | 2010-08-20 | 2011-08-12 | Improved anti-serum albumin binding variants |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013003899A2 true BR112013003899A2 (pt) | 2016-06-07 |
Family
ID=44582955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013003899A BR112013003899A2 (pt) | 2010-08-20 | 2011-08-12 | domínio variável único da imunoglobina anti-albumina sérica (sa), ligando multiespecífico, proteína de fusão, composição, ácido nucleico, vetor, célula hospedeira isolada, e, método de tratar ou previnir uma doença ou distúrbio em um paciente |
Country Status (12)
Country | Link |
---|---|
US (1) | US20130230519A1 (pt) |
EP (1) | EP2606065A2 (pt) |
JP (2) | JP2013537421A (pt) |
KR (1) | KR20130055663A (pt) |
CN (1) | CN103282381A (pt) |
AU (1) | AU2011290797A1 (pt) |
BR (1) | BR112013003899A2 (pt) |
CA (1) | CA2808683A1 (pt) |
EA (1) | EA201390116A1 (pt) |
MX (1) | MX2013002055A (pt) |
SG (1) | SG188204A1 (pt) |
WO (1) | WO2012022703A2 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL310340A (en) * | 2016-12-07 | 2024-03-01 | Ablynx Nv | Immunoglobulin sites with a single variable enhance serum albumin binding |
CA3050575A1 (en) | 2017-01-17 | 2018-07-26 | Ablynx Nv | Improved serum albumin binders |
SG11201906341XA (en) | 2017-01-17 | 2019-08-27 | Ablynx Nv | Improved serum albumin binders |
GB201818460D0 (en) * | 2018-11-13 | 2018-12-26 | Crescendo Biologics Ltd | Single domain antibodies that bind human serum albumin |
WO2020172528A1 (en) * | 2019-02-22 | 2020-08-27 | Anwita Biosciences, Inc. | Albumin binding antibodies and use thereof |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
PT1517921E (pt) | 2002-06-28 | 2006-09-29 | Domantis Ltd | Ligandos duplamente especificos com semi-vida no soro aumentada |
US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
EP2172553A1 (en) | 2004-03-24 | 2010-04-07 | Domantis Limited | Gas1 universal leader |
KR20120133403A (ko) | 2004-06-01 | 2012-12-10 | 도만티스 리미티드 | 증강된 혈청 반감기를 가지는 이특이성 융합 항체 |
RU2428431C2 (ru) | 2004-12-02 | 2011-09-10 | Домантис Лимитед | Слитые конструкции лекарственного средства и конъюгаты |
GB0521621D0 (en) | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
KR20080077261A (ko) * | 2005-12-06 | 2008-08-21 | 도만티스 리미티드 | Egfr 및/또는 vegf에 대해 결합 특이성이 있는리간드 및 그의 사용 방법 |
EP2441838A3 (en) | 2006-01-24 | 2013-07-10 | Domantis Limited | Fusion proteins that contain natural junctions |
CA2683791A1 (en) * | 2007-06-06 | 2008-12-11 | Domantis Limited | Polypeptides, antibody variable domains & antagonists |
GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
CN101932608A (zh) | 2007-11-30 | 2010-12-29 | 葛兰素集团有限公司 | 抗原结合构建体 |
BRPI0909397A2 (pt) * | 2008-03-31 | 2015-12-15 | Glaxo Group Ltd | composição, uso de uma composição, formulação, dispositivo de liberação, ácido nucléico, vetor, célula hospedeira, e, métodos para produzir um polipeptídeo de fusão |
MX2011005874A (es) * | 2008-12-05 | 2011-06-27 | Glaxo Group Ltd | Metodos para seleccionar polipeptidos resistentes a proteasa. |
WO2010081787A1 (en) | 2009-01-14 | 2010-07-22 | Domantis Limited | IMPROVED TNFα ANTAGONISM, PROPHYLAXIS & THERAPY WITH REDUCED ORGAN NECROSIS |
-
2011
- 2011-08-12 EP EP11745761.4A patent/EP2606065A2/en not_active Withdrawn
- 2011-08-12 EA EA201390116A patent/EA201390116A1/ru unknown
- 2011-08-12 SG SG2013010533A patent/SG188204A1/en unknown
- 2011-08-12 AU AU2011290797A patent/AU2011290797A1/en not_active Abandoned
- 2011-08-12 WO PCT/EP2011/064000 patent/WO2012022703A2/en active Application Filing
- 2011-08-12 KR KR1020137007052A patent/KR20130055663A/ko not_active Application Discontinuation
- 2011-08-12 CA CA2808683A patent/CA2808683A1/en not_active Abandoned
- 2011-08-12 JP JP2013524433A patent/JP2013537421A/ja active Pending
- 2011-08-12 US US13/817,883 patent/US20130230519A1/en not_active Abandoned
- 2011-08-12 CN CN2011800505551A patent/CN103282381A/zh active Pending
- 2011-08-12 BR BR112013003899A patent/BR112013003899A2/pt not_active IP Right Cessation
- 2011-08-12 MX MX2013002055A patent/MX2013002055A/es not_active Application Discontinuation
-
2015
- 2015-08-17 JP JP2015160365A patent/JP2016027801A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2012022703A2 (en) | 2012-02-23 |
JP2013537421A (ja) | 2013-10-03 |
JP2016027801A (ja) | 2016-02-25 |
AU2011290797A1 (en) | 2013-04-11 |
SG188204A1 (en) | 2013-04-30 |
CA2808683A1 (en) | 2012-02-23 |
CN103282381A (zh) | 2013-09-04 |
EA201390116A1 (ru) | 2013-09-30 |
US20130230519A1 (en) | 2013-09-05 |
EP2606065A2 (en) | 2013-06-26 |
MX2013002055A (es) | 2013-07-22 |
KR20130055663A (ko) | 2013-05-28 |
WO2012022703A3 (en) | 2012-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012029280A2 (pt) | variante de domínio variável único de imunoglobulina antialbumina sérica, imunoglobulina anti-sa, ligando multiespecífico, proteína de fusão, composição, ácido nucleico, vetor, célula hospedeira isolada, e, uso de uma variante, ligando multiespecífico ou proteína de fusão | |
CY1120670T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi) | |
CY1117236T1 (el) | Μονοκλωνικα αντισωματα εναντι γλυπικανης-3 | |
CY1122476T1 (el) | Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (τfρι) | |
BR112017014328A2 (pt) | anticorpos compreendendo um domínio de ligação de antígeno dependente de concentração de íon, variantes de região fc, anticorpos de ligação à il-8, métodos de produção dos mesmos e para prolongamento ou redução da meia-vida de um anticorpo em plasma, composição farmacêutica, ácido nucleico, vetor, célula hospedeira | |
CY1121538T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi) | |
BR112018010084A2 (pt) | ligantes de pd1 e/ou lag3 | |
BR112014022692A8 (pt) | molécula de ligação de antígeno multiespecífica | |
CR20120506A (es) | PROTEÍNAS QUE SE UNEN AL TNF-a | |
EA201892691A1 (ru) | Однодоменный белок, связывающий сывороточный альбумин | |
CY1119539T1 (el) | Πληρως ανθρωπινα αντισωματα ειδικα για to cadμ1 | |
MX2015005328A (es) | Composiciones y metodos para la administracion selectiva de moleculas de oligonucleotidos a tipos de celulas. | |
NZ628851A (en) | Erythrocyte-binding therapeutics | |
BR112016014293A2 (pt) | região de fragmento cristalizável canino, anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, e, método para aumentar a atividade de uma célula imune | |
CY1120210T1 (el) | Παραλλαγες αντισωματων anti-tfpi με διαφορικη δεσμευση στην περιοχη ρη για βελτιωμενη φαρμακοκινητικη | |
EA201270174A1 (ru) | Отдельные связывающиеся вариабельные домены с улучшенными свойствами, направленные против сывороточного альбумина | |
AR090047A1 (es) | Dominio variable dual de inmunoglobulinas y sus usos | |
MX355255B (es) | Variantes de fc y métodos para su producción. | |
WO2013092983A3 (en) | Enzymatic conjugation of polypeptides | |
WO2013170272A3 (en) | Site-specific labeling and targeted delivery of proteins for the treatment of cancer | |
EA201171067A1 (ru) | Улучшенные связывающие сывороточный альбумин варианты | |
BR112013003899A2 (pt) | domínio variável único da imunoglobina anti-albumina sérica (sa), ligando multiespecífico, proteína de fusão, composição, ácido nucleico, vetor, célula hospedeira isolada, e, método de tratar ou previnir uma doença ou distúrbio em um paciente | |
EA201591191A1 (ru) | Антитела против ntb-a и связанные с ними композиции и способы | |
UY32450A (es) | Variantes de unión a anti-albúmina de suero mejoradas | |
BRPI0720879A2 (pt) | microvesícula derivada de fermento carreador de fator de tecido (tf), composição e composição farmacêutica que a compreende, processos para a sua manufatura, proteína lipida de fator de tecido (tf) modificado, polinucleotídeo, vetor, célula hospedeira e anticorpo. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |